Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer
- 7 September 2006
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 24 (5) , 442-447
- https://doi.org/10.1016/j.urolonc.2005.08.011
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV MelanomaJournal of Clinical Oncology, 2005
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunityNature Reviews Immunology, 2004
- Immunotherapy for Urological MalignanciesJournal of Urology, 2004
- The Emerging Role of CTLA-4 as an Immune AttenuatorImmunity, 1997
- B7-1 and B7-2 Have Overlapping, Critical Roles in Immunoglobulin Class Switching and Germinal Center FormationImmunity, 1997
- Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivoInternational Immunology, 1996
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity, 1995
- Clonal Expansion Versus Functional Clonal Inactivation: A Costimulatory Signalling Pathway Determines the Outcome of T Cell Antigen Receptor OccupancyAnnual Review of Immunology, 1989